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Introduction
Fanconi anemia (FA) is a genomic instability disorder with phenotypes including progressive bone marrow failure (BMF), developmental abnormalities, and increased occurrence of leukemia and cancer 1 . To date 16 genes have been implicated in FA, and their products form a common DNA repair network ("FA pathway") 2, 3 . Since FA cells are hypersensitive to DNA interstrand cross-links (ICLs), the FA pathway has been considered to be involved in the repair of ICLs 2,3 . However, it remains unclear what type of endogenous DNA damage is repaired through the FA pathway. Recent studies have suggested that FA cells are also sensitive to aldehydes 4 , which may create DNA adducts including ICLs or DNA-protein crosslinks. Furthermore, double knockout mice deficient in Fancd2 and Aldh2, but neither of the single mutant mice, display an accelerated development of leukemia and BMF 5, 6 . On the other hand, Fanc-deficient mice in general do not fully recapitulate the human FA phenotype, including overt BMF 7 . Thus, the role of aldehydes in the pathogenesis of human FA is still uncertain.
ALDH2 deficiency resulting from a Glu504Lys substitution (rs671, hereinafter referred to as the A allele) is highly prevalent in East Asian populations. The A allele (Lys504) acts as a dominant negative, since the variant form can suppress the activity of the Glu504 form (G allele) in GA heterozygotes by the formation of heterotetramers 8 . Individuals with the A variant experience flushing when drinking alcohol, and have an elevated risk of esophageal cancer with habitual drinking 9 . Because the frequency of the A allele is close to 50% in the Japanese population at large, some Japanese FA patients are expected to be deficient in ALDH2. We thus set out to determine the ALDH2 status in a collection of Japanese FA patients. 6 The onset of BMF was defined according to the criteria used in the International Fanconi Anemia Registry (IFAR) study 10 . Criteria for diagnosis of aplastic anemia and other conditions are described in Supplemental Methods. We observed physical abnormalities characteristic of FA, including skin abnormalities (hyperpigmentation and café au lait spots), low birth weight, growth defects, and malformations affecting skeletal systems and deep organs. Extensive malformation was defined as the involvement of at least three sites including at least one deep organ 11 . Mutation analysis of FANCA/FANCC/FANCG genes 12 , ALDH2 genotyping 13 , Multiplex Ligation-mediated Probe Amplification (MLPA) test for FANCA (Falco), and whole exome sequencing (WES) 14 were done as previously described.
Methods
Details are provided as supplemental methods. Development of BMF or acute myeloid leukemia (AML)/myelodysplasia (MDS) was analyzed by the Kaplan-Meier method or the cumulative incidence method 15, 16 , respectively, since competing events (e.g., death and stem cell transplantation (SCT)) existed in AML/MDS but not in BMF. This study was approved by the Research Ethics Committee of the Tokai University Hospital and Kyoto University.
We obtained family informed consent from all subjects involved in this work.
Results and Discussion
All of the patients in this study (n=64, supplemental Table 1 ) were referred to the Tokai University Hospital because of pancytopenia, in some cases with MDS or leukemia. The clinical diagnosis of FA was made based on clinical presentation and Diepoxybutane (DEB)induced chromosome fragility tests in peripheral blood lymphocytes 17 , except for three cases in which the DEB test was negative due to FANCA reversion mosaicism (supplemental Table   1 and 2). Most of the patients underwent allogeneic SCT, indicating that our patients probably represent a FA population with relatively severe hematological symptoms.
To determine which FA gene was mutated in each of these patients, we applied combinations of PCR-based methods (n=26), the MLPA test for FANCA mutations (n=44), and WES (n=29). In our WES analysis, more than 90% of the 50 Mb target sequences were analyzed by greater than ten independent reads (data not shown). 59 patients were found to have a mutation in FA genes in at least one allele, but 5 of them were mutation-free in the known 16 FA genes, even after WES (Table 1 and supplemental Table 1 ). These unclassified cases might be caused by large deletions or intronic mutations that are difficult to detect with these methods 18 , or possibly mutations in a novel FA gene.
We determined the ALDH2 genotype in our series of 64 patients (Table 1 and supplemental Table 1 ). The distribution of the ALDH2 variant alleles appeared not significantly different from the reported allele frequencies in the healthy Japanese population 13 . The occurrence of leukemia and/or MDS was also not significantly different between patients with GA and GG genotypes. Strikingly, however, we found that progression of BMF was accelerated in heterozygous carriers of the variant A allele compared to homozygous GG patients ( Figure 1A and B ). Moreover, the three individuals carrying AA alleles developed MDS with BMF at a very young age ( Figure 1A and B). None of these three patients belonged to FA-D1 or FA-N, the FA subgroups with severe symptoms 19, 20 .
Patient number 3 had biallelic frameshift mutations (S115AfsX11) in FANCP/SLX4. By contrast, of the FA-P patients that have previously been reported, none have displayed particularly severe symptoms [21] [22] [23] .
FA is a heterogeneous disorder, and our cohort of patients is quite heterogeneous in terms of complementation groups and types of mutations (Table 1 ). In order to reduce some of the variability, we selected only the FANCA patients having nonsense, frameshift, or large deletion mutations identified at both alleles, (n=12, supplemental Table 1 ), and repeated the analysis. A patient with probable FANCA reversion (patient number 55) was excluded. In this subset of patients, a highly significant statistical difference was reproduced in BMF progression ( Figure 1C ) but not in AML/MDS development (data not shown).
We could not detect any significant difference in terms of % birth weight ( Figure 1D) or number of physical abnormalities ( Figure 1E ) that correlated with the ALDH2 genotypes.
However, a significant difference was observed in the incidence of each class of malformations in the case of radial, cardiovascular, skeletal, or kidney anomalies, and in the incidence of extensive malformation ( Figure 1F ).
In conclusion, our current data indicate that endogenous aldehydes are an important source of genotoxicity in the human hematopoietic system, and the FA pathway counteracts them. If the FA pathway is compromised, hematopoietic stem cells (HSCs) likely accumulate aldehyde-induced DNA damage, resulting in BMF due to p53/p21-mediated cell death or senescence 6, 24 . Consistent with this model, a recent study showed that the HSCs in aldh2/fancd2 double knockout mice accumulate more DNA damage than HSCs in either of the single knockout mice 6 . Since some ALDH2-proficient FA patients developed BMF early, other modifier genes or environmental factors might affect levels of aldehydes or other genotoxic substances. Interestingly, our data predict that Japanese FA patients in general develop BMF at an earlier age compared to patients of other ethnic origins. We need to establish a Japanese FA registry similar to IFAR to test whether this is true or not. Finally, it seems worth considering ALDH2 agonists such as Alda-1 as protective drugs against BMF in FA patients. Alda-1 can stimulate the enzymatic activity of both the normal and variant ALDH2 25 , suggesting that Alda-1 or a similar drug could be beneficial even for ALDH2proficient FA cases. 
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Supplemental Methods
Patients. Diagnosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is based on morphological criteria described by the FAB committee. Aplastic anemia (AA) is defined as hypoplastic marrow with two of the following: neutrophil count <1.5 x 10 9 /l, platelet count <100 x 10 9 /l, and hemoglobin level <10g/dl. Severe AA (SAA) is defined as hypoplastic marrow with two of the following: neutrophil count <0.5 x 10 9 /l, platelet count <20 x 10 9 /l, and reticulocyte count <20 x 10 9 /l. The onset of BMF was defined as the time when one of the following laboratory parameter values used in the International Fanconi Anemia Registry study 1 was observed: a platelet count <100 X 10 9 /L, a hemoglobin level < 10 g/dl, or an absolute neutrophil count <1 X 10 9 /L 1 .
PCR, sequencing, and Taqman PCR. Genomic DNA or total RNA was isolated from either PHA-stimulated lymphocytes or cultured fibroblasts using Puregene (Qiagen) or RNAeasy (Qiagen) kits, respectively. cDNA was synthesized with a Primescript II cDNA synthesis kit (Life Technologies). Mutation analyses of cDNA and genomic DNA samples regarding FANCA, FANCC, or FANCG were carried out by PCR and direct sequencing as previously described 2 . In addition, 45 patients were examined by the Multiplex Ligation-mediated Probe Amplification (MLPA) test for FANCA (Falco Biosystems). Additional patients (n=29) were screened by whole exome sequencing for mutations in the known 16 FA genes as described below. The ALDH2 genotype was determined by a previously established Taqman-PCR assay 3 . In cases #43 and #59, we have not yet determined whether the Exon 27 deletion is associated with a c.2546delC mutation or not. 
